A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depressionÉimear M. Foley, Golam M. Khandaker, Muzaffer Kaşer et al.|Psychoneuroendocrinology|2024Cited by 32
Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosisÉimear M. Foley, Golam M. Khandaker, Jack Rogers et al.|BMJ Open|2023Cited by 22
Neurocognitive Performance in Depressed Patients with low-grade inflammation and somatic symptomsMuzaffer Kaşer, Golam M. Khandaker, Éimear M. Foley|Brain Behavior & Immunity - Health|2021Cited by 12
A novel marker of interleukin 6 activity and clinical and cognitive outcomes in depressionÉimear M. Foley, Golam M. Khandaker, Muzaffer Kaşer et al.|Brain Behavior and Immunity|2023Cited by 0
Interleukin 6 as a Treatment Target for DepressionÉimear M. Foley, Golam M. Khandaker, Muzaffer Kaşer et al.|JAMA Psychiatry|2026Cited by 0